Scientific deep-dive
What Is Petrelintide? Zealand's Long-Acting Amylin Analog
Petrelintide is Zealand Pharma's investigational long-acting amylin analog, with published human data through phase 2. We cover what amylin analogs are for, how early 'early' really is, and why early-phase figures cannot be compared to phase 3 results.
Petrelintide is an investigational long-acting human amylin analog from Zealand Pharma. Like cagrilintide, it acts on the amylin system rather than the GLP-1 system — a genuinely different mechanism, not a stronger version of the drugs already on the market [3]. It is at an earlier stage than most compounds people ask about: the published human data run from phase 1 [2] to one phase 2 trial [4], and it has no approval anywhere.
What amylin analogs are for
Amylin is released with insulin from pancreatic beta cells and reduces meal size through its own receptor pathway. The interest in analogs of it is partly about added weight loss and substantially about tolerability: the search for better-tolerated weight-loss drugs is the explicit framing in the review literature [3], because GLP-1 discontinuation is frequently driven by gastrointestinal side effects rather than lack of effect.
Petrelintide was engineered for potency, stability and a long half-life so it can be dosed weekly [1] — the same design problem cagrilintide solves, approached by a different company.
How early is early
The published clinical evidence starts with two randomized, controlled phase 1 trials reporting safety, tolerability, pharmacokinetics and pharmacodynamics for weight management [2]. Phase 1 trials are designed to answer whether a drug is tolerable and how the body handles it — not whether it works better than an existing treatment.
The first efficacy data come from ZUPREME 1, a 42-week phase 2 trial published in Lancet Diabetes & Endocrinology in 2026 that randomly assigned 493 adults without type 2 diabetes to weekly petrelintide (maintenance doses of 1.0 to 9.0 mg) or placebo [4]. At the primary 28-week endpoint, mean weight change by the efficacy estimand was −7.9% to −9.8% across doses versus −1.7% on placebo, with reductions of up to −10.7% by week 42. Nausea was the most common adverse event (20% vs 6% on placebo); vomiting occurred in 3% vs 6%.
It is not available, in any form
Petrelintide has no approval and no prescription route. As with every unapproved compound in this class, anything offered for sale under the name is unapproved material rather than a trial drug — and with only phase 1 and phase 2 trials published, the total human safety experience is smaller than for almost anything else being sold that way.
For Eli Lilly's amylin candidate, see what is eloralintide?, which covers its 48-week phase 2 trial.
Frequently Asked Questions
References
- 1.Fischer Munch H, Just R, Mosolff Mathiesen J, Eriksson PO, Skodborg Villadsen J, Vestergaard B, et al. Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. J Med Chem. 2025. PMID: 41217931.
- 2.Brændholt Olsen M, Griffin J, Hövelmann U, Macura S, Fredsted Hagen B, Hesse D, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes Obes Metab. 2026. PMID: 42017294.
- 3.Alhazmi A, le Roux CW. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. Diabetes Obes Metab. 2026. PMID: 42452898.
- 4.Garvey WT, Ard J, Connery L, Frias JP, le Roux CW, Pietiläinen KH, et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2026. PMID: 42810355.
Related research
What Is Cagrilintide? The Amylin Analog Behind CagriSema
Cagrilintide is a once-weekly amylin analog from Novo Nordisk and the other half of CagriSema. Neither has FDA approval. We cover what amylin analogs actually are, the pooled trial evidence across 5,425 participants, and why there is no cagrilintide dosage chart to follow.
6 min read
What Is Eloralintide? Lilly's Amylin Weight-Loss Drug Explained
Eloralintide is Eli Lilly's investigational once-weekly amylin drug. In a 48-week phase 2 trial people lost about 20% of body weight on higher doses, with nausea and fatigue as the main side effects. How it works, the trial results, and the phase 3 timeline.
7 min read
Cagrilintide: The Amylin Analogue Behind CagriSema — What the Evidence Shows
Cagrilintide is Novo Nordisk's investigational long-acting amylin analog and the amylin half of CagriSema. The phase 2 monotherapy trial showed about -10.8% weight loss at 26 weeks. What it is, the trial data, and what it means for patients.
8 min read
REDEFINE: The Full CagriSema Trial Program (2026)
The full CagriSema REDEFINE program: REDEFINE 1 (22.7% adherent weight loss), REDEFINE 2 in diabetes, and the REDEFINE 4 head-to-head miss versus tirzepatide.
13 min read
Beyond Wegovy and Zepbound: Three Pipeline GLP-1 Drugs to Watch
Three challenger GLP-1 drugs not made by Lilly or Novo: survodutide (Boehringer Ingelheim and Zealand), maridebart cafraglutide (Amgen's MariTide), and ecnoglutide (Sciwind). This guide covers the published phase 2 and 3 data and mechanisms for each, and where they fit.
11 min read
Bimagrumab: The Muscle-Preserving Weight-Loss Antibody — Evidence Review
Bimagrumab is an investigational antibody that blocks ActRII to build muscle while cutting fat — the opposite of GLP-1 muscle loss. Phase 2 evidence: -20.5% fat, +3.6% lean, plus the BELIEVE bimagrumab + semaglutide trial.
9 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Pricing Compare
Get started →Ro
FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Read full review →Pricing Compare
Get started →Collective
The lowest flat medication price if you can absorb an annual membership fee
Read full review →Pricing Compare
Get started →